AndersonBrecon, Inc.

1. Primary objective: To determine whether SZC is superior to placebo in slowing CKD progression as an adjunct to ACEi/ARB therapy 2. Secondary objectives: a. To determine whether SZC is superior to placebo in reducing the incidence of the composite endpoint of renal failure as an adjunct to ACEi/ARB therapy b. To determine whether SZC is superior to placebo in reducing the incidence of lisinopril/valsartan dose reduction in subjects receiving lisinopril/valsartan at randomization as an adjunct to ACEi/ARB therapy c. To determine whether SZC is superior to placebo in reducing albuminuria as an adjunct to ACEi/ARB therapy d. To determine whether SZC is superior to placebo in increasing serum bicarbonate levels as an adjunct to ACEi/ARB therapy e. To determine whether SZC is superior to placebo in maintaining normal serum potassium levels as an adjunct to ACEi/ARB therapy 3. Safety Objectives To evaluate the safety and tolerability of SZC as an adjunct to ACEi/ARB therapy compared with placebo

The overall response rate (ORR) of ibrutinib in treatment-naïve patients with CLL/SLL was estimated according to the International Working Group on Chronic Lymphocytic Leukemia (iwCLL) consensus guidelines.

1) Primary Objective: To evaluate the effectiveness of sodium zirconium cyclosilicate (SZC) compared with placebo in reducing the incidence of the primary composite endpoint of SCD, all strokes, or hospitalizations/interventions/emergency department (ED) visits for arrhythmias 2) Secondary Objectives: a. To evaluate the effectiveness of SZC compared with placebo in maintaining normal blood potassium levels at 1 year b. To evaluate the effectiveness of SZC compared with placebo in reducing the incidence of hospitalizations/interventions/ED visits for arrhythmias c. To evaluate the effectiveness of SZC compared with placebo in reducing hospitalizations/interventions/ED visits for arrhythmias d. To evaluate the effectiveness of SZC compared with placebo in reducing the need for emergency treatment for hyperkalemia e. To evaluate the effectiveness of SZC compared with placebo in preventing severe hyperkalemia at 1 year f. To evaluate the effectiveness of SZC compared with placebo in reducing the incidence of SCD g. To evaluate the effectiveness of SZC compared with placebo in reducing the incidence of all strokes h. To evaluate the effectiveness of SZC in reducing the incidence of CV death compared with placebo i. To evaluate the effectiveness of SZC in reducing the incidence of all-cause death compared with placebo 3) Safety objectives: a. To evaluate the safety and tolerability of SZC compared with placebo in subjects undergoing hemodialysis